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Despite the significant progress made over the past decade in the development of more effective and better tolerated agents to prevent chemotherapy-induced emesis, it still remains a significant, unresolved issue in a number of clinical situations, including cisplatin-induced delayed emesis, multiple and very-high dose chemotherapy (Roila, 1996; Frakes et al., 1997) .
Numerous neurotransmitters have been implicated in triggering emesis; however, Substance P (SP 2 ), an 11-amino acid neuropeptide of the tachykinin family of peptides, by virtue of its localization in both gut and central nervous system, and its ability to produce vomiting when injected in ferrets, is thought to play a key role in emetic response (Watson et al., 1995a) . SP binds to a specific neuroreceptor, neurokinin 1 (NK1) and therefore, a number of nonpeptide compounds that selectively block the NK1 receptor have been evaluated as the antiemetic agents (Watson et al., 1995b; Gardner et al., 1996; Gonsalves et al., 1996; Grelot et al., 1998; Diemunsch and Grelot, 2000) .
Ezlopitant, (2-benzhydryl-1-aza-bicyclo[2.2.2]oct-3-yl)-(5-isopropyl-2-methoxy-benzyl)-amine, Fig. 1 ) is a highly potent and selective NK1 receptor antagonist with Ki of 0.4 nM (Evangelista, 2001 ). It acts on the CNS to exert the excellent anti-emetic activity for the control of both acute and delayed emesis induced by cisplatin in ferrets at a dose of 3 mg/kg (Tsuchiya et al., 2002 (Tsuchiya et al., , 2005 . It also inhibited SP-induced contraction of guinea pig trachea with a pA 2 value of 7.8, but had no effects on the baseline tension and maximum contractile response. Recent clinical studies have shown that ezlopitant is effective for the treatment of either acute or delayed phase of emesis associated with anti-neoplastic treatment using cisplatin, suggesting a role of NK1 receptor antagonists in the clinic for the control of emesis to improve the quality of life of cancer patients undergoing chemotherapy (Hesketh et al., 1999; Lee et al., 2000) .
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8 240-264 h post-dose. One of the subjects (#1) was removed from the study after 48 h due to personal reasons. The total volumes of urine samples were recorded after each collection. Feces were collected as passed, from time of dosing until 264 h after dosing.
Blood sufficient to provide a minimum of 4 ml of serum was collected, in evacuated tubes containing no anticoagulants, phase separator or preservative, from each subject at 0 (predose), 0.5, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 120, 144, 168, 192, 216 and 240 h after the dose. In addition, blood sufficient to yield 5 ml of serum was collected at 2, 5 and 12 h after dosing for metabolite identification. The serum was allowed to clot at room temperature and was separated within 1 h from the whole blood in a refrigerated centrifuge, transferred into labeled plastic tubes, and immediately frozen.
Determination of Radioactivity. Radioactivity in urine, feces, and serum was measured by liquid scintillation counting. Aliquots of serum and urine (0.2-1.0 ml, in triplicate) for each sampling time were mixed with 5 ml of Ecolite (+) scintillation cocktail and counted in a Wallac 1409 (Gaithersburg, MD) or a Packard 2500 (Downers Grove, IL) liquid scintillation counter.
Fecal samples were placed into Stomacher 400 bags and homogenized in equal amounts of water to a thick slurry, using a Stomacher homogenizer from Cooke laboratory Products (Alexandria, VA). Aliquots (30-200 mg) of the fecal homogenates were air dried prior to combustion in an automatic sample oxidizer (Packard oxidizer model 307). Radioactivity in the combustion products was determined by trapping the liberated CO 2 in Carbo-sorb followed by liquid scintillation counting using Permafluor E+ as a scintillation cocktail. Combustion efficiency of the oxidizer was determined by combustion of the [ 14 C]methyl methacrylate standard in an DMD #15362 9 identical manner. Radioactivity less than twice the background value was considered to be below the limit of determination.
Samples collected prior to dosing were used as controls and counted to obtain a background count rate. Radioactivity in the dose was expressed as 100% and the radioactivity in urine and feces at each sampling time was defined as the percentage of dose excreted in the respective matrices at that sampling time. The amount of radioactivity in serum was expressed as nanogram-equivalents of parent drug per mililiter and was calculated by using the specific activity of the dose administered.
Pharmacokinetic Analysis. Serum concentrations of ezlopitant were quantitated by an LC/MS/MS assay (Kamel et al., 2000) . Pharmacokinetic parameters (PK) were determined using the WinNonlin-Pro Ver. 1.5 program (Pharsight, Mountain View, CA) by non-compartmemtal analysis.
Extraction of Metabolites from Biological Samples.
Urine samples obtained at 0-12, 12-24, 24-48 and 48-72 h post-dose were pooled base on collected weight for each subject, which accounts for greater than 90% of the urine radioactive excreta. The pooled urine samples (8 ml)
were lyophilized overnight. The residues were reconstituted in 0.25 ml of acetonitrile:20 mM ammonium acetate (20:80) and aliquots (200 µl) were injected onto the HPLC column.
Fecal homogenates containing the highest levels of excreted radioactivity (0-96 h) were pooled, and the pooled samples (~10 g) were extracted with 2 x 20 ml of acetonitrile. The two supernatants were combined and aliquots of 0.5 ml were counted in duplicate to determine This article has not been copyedited and formatted. The final version may differ from this version. Serum samples (3 ml, 1 ml from each at 2, 5 and 12 h time point) were extracted with 2 x 6 ml of acetonitrile. The mixtures were vortex mixed for 5 min and centrifuged at 3500 rpm for 5 min to remove the precipitated proteins. Supernatants were combined and a small aliquot of supernatant was counted. Approximately 90% of the radioactivity was recovered in the supernatant. The supernatants were concentrated to dryness in a nitrogen Turbo Vap LV evaporator at a room temperature. The residues were reconstituted in 150 µl of acetonitrile/20 mM ammonium acetate (20/80), centrifuged to remove insoluble matters, and 100 µl aliquots were injected onto the HPLC column.
Reaction with Dansyl Chloride. The metabolites M1A, M1B and M4 from human urine were isolated by HPLC. The HPLC eluent from regions for metabolites M1A, M1B and M4 were collected and evaporated to dryness. The residues were treated with 100 µl of 100 mM sodium bicarbonate solution. A 50 µl aliquot of each reconstituted fraction was reacted with 25 µl of dansyl chloride solution (1 mg/ml in acetone). The mixture was allowed to stand at room temperature for 10 min and then evaporated to dryness. The residue was reconstituted in 150 µl of acetonitrile/20 mM ammonium acetate (20/80), centrifuged to remove insoluble matters, and 100 µl aliquot was injected onto the HPLC column.
This article has not been copyedited and formatted. The final version may differ from this version. Reaction with Methanol/Sulfuric Acid. The dried fecal extract was treated with 0.25 ml of 10% sulfuric acid in methanol. The mixture was allowed to stand at room temperature for 4 h.
The solvents were evaporated to dryness and the residue was reconstituted in 150 µl of acetonitrile/20 mM ammonium acetate (20/80). The mixture was centrifuged to remove insoluble matters, and 100 µl aliquot was injected onto the HPLC column.
Chromatography. The HPLC system consisted of a HP-1050 solvent delivery system, a HP- CID studies were performed using argon gas at a collision energy of 30-40 eV.
Results

Mass Balance
After a single oral dose of [ 14 C]ezlopitant to human subjects, a major portion of the administered radioactivity was excreted in the feces. By 264 h after the dose, the mean cumulative excretion amounted to 32.0 ± 4.2% in the urine and 50.8 ± 1.4% in the feces (Table 1 ). In total, 82.8% of the radioactive dose was recovered in urine and feces (Table 1) . Of the entire radioactivity recovered in urine, approximately 83% was excreted in the first 48 h. Because feces were collected after natural defecation, the fecal elimination of radioactivity was delayed, compared with that in urine. The major portion of radioactivity (~88%) in feces appeared during 24-144 h This article has not been copyedited and formatted. The final version may differ from this version. 
Pharmacokinetics
Mean serum concentration-time curves for ezlopitant and total radioactivity are shown in fig. 2 and the calculated pharmacokinetic parameters are shown in Table 2 .
The absorption of ezlopitant was rapid, as indicated by early appearance of radioactivity in serum after oral administration. Serum concentrations for ezlopitant and total radioactivity peaked at ~2 hr after oral administration (Table 2) . C max values for the parent drug ranged from 193 to 370 ng/ml with a mean value of 271 ng/ml. C max values for the total radioactivity ranged from 938 to 2024 ng equiv./ml with a mean value of 1456 ng equiv/ml. These values were five times higher than those of the parent drug, suggesting that a major portion of the circulating radioactivity was attributable to metabolites. The mean terminal phase T 1/2 values were 13.0 and 108.9 h for parent drug and total radioactivity, respectively. Mean AUC (0-t) values for parent drug and total radioactivity were 3257 ng.h/ml and 34,029 ng equiv.h/ml, respectively.
Metabolic Profiles in Biological samples.
Urine. A representative HPLC radiochromatogram for metabolites in urine is shown in fig. 3 . A total of 12 metabolites were detected in the radiochromatogram. The percentages of metabolites in relation to the administered dose are presented in Table 3 . The major metabolites in urine were due to cleaved products, which were resulted by oxidative dealkylation of the 2-This article has not been copyedited and formatted. The final version may differ from this version. approximately 34% of the total radioactivity in urine, were identified as benzyl amine derivatives.
Feces. On average, ~96% of the radioactivity was recovered after extraction of fecal samples. A representative HPLC radiochromatogram for fecal metabolites is shown in fig. 3 . A total of 8 radioactive peaks were detected in the radiochromatogram. The percentages of fecal metabolites in relation to the administered dose are presented in Table 3 . The major metabolites in feces were due to hydroxylation at the isopropyl moiety. The metabolites M12 and M14, corresponding to for 67% of the total radioactivity in feces, were identified as 1,2-propane diol and ω-carboxy metabolites.
Circulating Metabolites
A representative HPLC radiochromatogram of circulating metabolites is shown in Fig. 4 .
Ezlopitant and a total of 5 metabolites were detected. The relative percentages of circulating metabolites are presented in Table 4 . The major circulating metabolites were due to oxidation at the isopropyl moiety. Metabolites M12 and M16 (CJ-12,764) accounting for approximately 84% of the total circulating radioactivity between 2-12 hr period , based on the pooled samples, were identified as 1,2-propane diol and Propan-2-ol (ω-1 hydroxy metabolite). Unchanged ezlopitant and its alkene metabolite accounted for only <8% of the total radioactivity.
Mass spectral fragmentation of ezlopitant
Ezlopitant had a retention time of ~38.7 min on the HPLC system. Table 5 ). The structure assignments of major fragment ions are proposed in fig. 5B .
Identification of Metabolites
Metabolites M1A, M1B, M4. M1A, M1B and M4 had the retention times of ~3.1, 5.7, and 8.3
min, respectively, on HPLC and they were found only in urine. The full scan MS of M1A, M1B
and M4 produced protonated molecules of m/z 198, 182 and 196, respectively, suggesting that they all were cleaved products. Further the even mass of protonated molecular ions suggested that they had an odd number of nitrogen atoms.
The fragment ion at m/z 165, loss of 17 Da (NH 3 ), indicated the presence of a primary amine, loss of a methyl group and addition of an oxygen atom ( Table 5 ). Based on these data, M12 was tentatively identified as 2-{3-
On the other hand, CID spectrum of M15 showed major fragment ions at m/z 179, 167, 161, 123
and 110 ( Fig 9B, Table 5 
Discussion
We here report the metabolic fate and disposition of ezlopitant following oral administration of a 200 mg dose of [ 14 C]ezlopitant, labeled at the benzylic carbon of the isopropyl anisole ring, to four healthy male volunteers. On average total radioactivity recovered from subjects was 83% not including one of the subjects that did not continue on the study after 48 h post dose. The majority of the radioactivity was excreted in the feces, suggesting that fecal/biliary excretion was This article has not been copyedited and formatted. The final version may differ from this version. the major route of elimination of ezlopitant and its metabolites. The radioactivity recovered in urine accounts for 32% of the dose.
After oral administration, the serum concentrations of total radioactivity were greater than the parent compound at all time points. This suggested the early formation of metabolites.
Unchanged ezlopitant accounted for only ~9.5% of the total radioactivity in serum pooled from 0-12 hr period. M16 and ω, ω -1-dihydroxy ((1, 2-dihydroxy, M12) were identified as the major circulating metabolites accounting for approximately 64.6 and 15.4% of total circulating radioactivity pooled from 0-12 hr period, respectively. The half-life for total radioactivity was higher than the unchanged drug suggesting that the elimination of metabolites was much slower than that of parent compound in humans.
Unchanged elimination of ezlopitant was an insignificant portion of the total elimination such that there was no unchanged drug detected in urine and feces. A total of 13 metabolites were identified. The metabolites were characterized by LC-MS/MS with simultaneous online radioactivity monitoring, which is clearly a technique of choice for the rapid structural characterization of metabolites from biological fluids (Johnson et al., 2003; Kamel and Prakash, 2006) . The structures of two metabolites, M16 and M17 were confirmed by comparisons of their HPLC retention times and CID product ion spectra to those of the synthetic standards. The structures of other metabolites were proposed based on molecular ions and fragmentation patterns and further supported by derivatization with acidic methanol or dansyl chloride. All the metabolites were formed from oxidative metabolism. Based on the structures of metabolites, a plausible scheme for the biotransformation pathways of ezlopitant in humans is depicted in fig. 1.
This article has not been copyedited and formatted. The final version may differ from this version. The major metabolic pathway of ezlopitant was due to the oxidation of the isopropyl side chain to form the ω-1-hydroxy-(M16; 6% in urine and 1 % in feces) and ω,ω -1-dihydroxy (M12;
8.12% in feces and 3.81% in urine) and ω-carboxy-(M14; 20.67% in feces and 1.65% in urine)
metabolites. The derivatization of M14 with acidic methanol supported the presence of a carboxyl group. Although, the ω-hydroxy metabolite was not identified either in urine or feces but it could be envisioned that M14 metabolite was formed by further oxidation of the ω-hydroxy metabolite. Hydroxylation at the tert-butyl-or isopropyl-side chains to form ω-hydroxy metabolites is not uncommon and, for example, was observed for several compounds containing these side chains (Ishida et al., 1998; Johnson et al., 2003) . M12 is a 1,2 dihydroxy metabolite which is most likely formed due to further oxidation of ω-1 hydroxy metabolite (M16) at the isopropyl group. Alternatively it could also be formed by further metabolism of the alkene metabolite (M17) (Obach 2000). Metabolites M12 and M15 produced the same protonated molecule of m/z 48 but the CID mass spectra of these metabolites were able to distinguish oxidative sites characterized by distinct product ions.
The major metabolites in urine were due to cleaved products resulted by oxidative dealkylation of In vitro studies using hepatic microsomes form humans and recomobinant human CYP 450
suggested that ezlopitant is metabolized predominantly by the CYP3A4/3A5, and to a lesser extent by CYP2D6 (Obach, 2000 and 2001) . (Obach 2000) . This suggests that elimination of ezlopitant is primarily relying on a single enzyme, which may contribute to patient-to-patient pharmacokinetic variability. The human CYP3A family, accounting for ~50% of the total P450 in human liver, is clinically very important because it has been shown to metabolize a large number of drugs (Wrighton et al., 1996) . The human CYP3A subfamily includes CYP3A4, CYP3A5, CYP3A7 (Li et al., 1995) , and CYP3A43 (Domanski et.al., 2001 ) as sub-family members. CYP3A4 is the major human liver CYP3A enzyme, whereas CYP3A5 is present in only ~10-30% of the human liver and CYP3A7 is only present in fetal liver. Although, ezlopitant is not a potent inhibitor of CYP3A, but since it is a substrate of this enzyme attention needs to be given when it is co-administered with CYP3A inhibitors.
In conclusion, the results of this study provide the first analysis of formation and excretion of metabolites of ezlopitant in humans. Ezlopitant is rapidly absorbed in humans. The majority of the total administered ezlopitant radioactivity was excreted in the feces. Ezlopitant was This article has not been copyedited and formatted. The final version may differ from this version. This article has not been copyedited and formatted. The final version may differ from this version. , 439, 193, 167, 163, 147, 123, 110 M20 18.0 503 195, 177, 167, 123, 110 This article has not been copyedited and formatted. The final version may differ from this version. 
